679 studies on GLP-1R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This research is profoundly important as Type 2 Diabetes (T2D) significantly elevates the risk of severe cerebrovascular events like stroke, and understanding semaglutide's direct impact on brain health is critical. I…
The anticipated findings from this study underscore the potential of semaglutide 2.4 mg as a highly effective treatment option for individuals managing both Type 2 Diabetes and obesity. By addressing both conditions s…
The high and increasing prevalence of adolescent severe obesity underscores the urgent need for more effective and sustainable treatment strategies. If successful, this trial could demonstrate that combining semagluti…
This study is profoundly crucial for validating the cardiovascular benefits of semaglutide 2.4 mg in a real-world setting, offering invaluable data that complements and extends findings from highly controlled clinical…
Understanding the optimal pre-procedural management for patients on GLP-1RAs like semaglutide is critical for patient safety and procedural efficacy during endoscopy. If a one-week discontinuation significantly reduce…
This study holds significant implications for the obesity treatment landscape. A successful outcome, demonstrating comparable or superior efficacy and safety, could introduce a new, potentially more accessible or cost…
Understanding age-specific brain responses to GLP-1RAs is critically important for optimizing obesity treatment strategies across the lifespan. This research could reveal fundamental differences in how the developing …
This research is important because it provides real-world evidence for oral semaglutide's effectiveness outside of highly controlled clinical trial settings. Understanding its performance in routine clinical practice,…
This study is significant because it specifically investigates Semaglutide's efficacy and safety in East Asian subjects, addressing a critical gap in demographic representation within clinical trials for overweight an…
The potential findings from this study could be transformative for obesity management, offering a strategy to mitigate the undesirable muscle loss often associated with significant weight reduction. If successful, thi…
This planned study holds significant promise, as it could establish a novel pharmacological strategy to improve outcomes for atrial fibrillation patients with obesity undergoing ablation. If successful, the findings w…
This foundational Phase 1 study is a critical early step in the development of NN9535 (semaglutide), a compound now widely known for its efficacy in type 2 diabetes and obesity. The successful completion of this trial…
This study is significant because it evaluates a novel approach to personalizing semaglutide treatment, which could revolutionize how obesity and excess weight are managed. By providing healthcare professionals with a…
The successful completion of this trial could have significant implications for the treatment landscape of Type 2 Diabetes. If QLG2065 demonstrates comparable efficacy and safety to Ozempic®, it would introduce a new,…
This study is significant because Semaglutide, a GLP-1 receptor agonist, is already approved for obesity and type 2 diabetes, conditions strongly linked to NAFLD. If the results demonstrate efficacy, it could provide …
The resurgence of cocaine use and related mortality underscores an urgent, unmet need for effective treatments. If Semaglutide proves effective in this pilot study, it could offer a novel pharmacological approach to C…
This study holds significant promise for identifying a novel therapeutic approach for alcohol use disorder (AUD), especially in the context of obesity and fatty liver disease, which are highly prevalent comorbidities.…
This research could fundamentally change our understanding of how GLP-1 RAs exert their metabolic benefits, extending beyond peripheral tissues to direct brain mechanisms. By clarifying the role of semaglutide in enha…
If the anticipated findings are confirmed, this study could provide crucial evidence for the broad metabolic benefits of GLP-1RAs beyond just glycemic control and weight loss. A detailed understanding of how these dru…
This pilot study is significant because it explores a novel adjunctive therapeutic strategy for Crohn's disease by targeting metabolic health and weight. If successful, it could demonstrate that GIP/GLP-1 receptor ago…
These findings are highly significant, establishing Tirzepatide as a potentially superior treatment option for individuals with Type 2 Diabetes who are at high risk for cardiovascular events. The dual benefits of subs…
The withdrawal of this study means a potential avenue for exploring enhanced weight loss and metabolic improvements, particularly through muscle preservation with Bimagrumab alongside Tirzepatide's established effects…
Persistent obesity after bariatric surgery represents a significant clinical challenge, often leading to comorbidities and reduced quality of life. If Tirzepatide proves effective and safe in this specific patient pop…
This pilot study is critically important as it addresses a significant unmet medical need for safe and effective weight management in obese kidney transplant recipients. Successful outcomes could establish Tirzepatide…
Understanding the extrapancreatic effects of GIP and GLP-1 is crucial for optimizing current and developing future treatments for type 2 diabetes and obesity. This research will provide critical insights into why comb…
This study is incredibly significant because it seeks to confirm if tirzepatide, a dual GLP-1 and GIP receptor agonist already approved for weight management, can directly improve long-term health outcomes beyond just…
This research is crucial because it addresses a significant unmet need for effective treatments targeting adiposopathy in a vulnerable population with CKD and Type 2 Diabetes. Understanding how GLP-1RAs impact fat dis…
The potential for tirzepatide, a dual GLP-1 and GIP receptor agonist, to address both obesity and methamphetamine use disorder simultaneously represents a significant advancement in addiction medicine and metabolic he…
Obtaining real-world data on Tirzepatide is paramount for understanding its performance and tolerability outside the highly controlled environment of earlier clinical trials. This study will provide invaluable insight…
The potential to preserve lean mass during GLP-1 induced weight loss is crucial for improving long-term health outcomes and metabolic function in individuals with obesity. Preventing muscle loss can enhance strength, …
The provided research record is a study protocol description from ClinicalTrials.gov and, as such, does not contain specific efficacy or safety results from the trial. The study, NCT06445075, is listed as COMPLETED, i…
The findings of this study are crucial for enhancing patient safety during surgical procedures for individuals on GLP-1/GIP agonists. If standard fasting guidelines prove insufficient, it could lead to revised pre-ope…
The bold challenge of weight regain after successful initial weight loss significantly impacts long-term health outcomes for individuals with obesity. If Retatrutide proves effective in maintaining weight reduction, i…
If successful, this trial could represent a significant advancement for patients with Type 2 Diabetes and renal impairment, a group with limited treatment options and high unmet medical need. Retatrutide could offer a…
If Retatrutide demonstrates a positive impact on renal function, it could represent a significant advancement in treating complex metabolic and renal diseases. As a triple GIP/GLP-1/glucagon receptor agonist, Retatrut…
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors, showing promise in weight loss and glucose control in earlier studies. If this Phase 1 trial demonstrates a significant positive impa…
This head-to-head Phase 3 trial is critically important because it directly compares retatrutide, a potential best-in-class GLP-1/GIP/Glucagon receptor triple-agonist, against semaglutide, a leading GLP-1 receptor ago…
Preventing muscle loss during significant weight reduction is critical for long-term health outcomes, as preserved muscle mass contributes to better metabolic function, strength, and overall quality of life. If succes…
This study provides crucial real-world evidence suggesting that GLP-1 RA initiation significantly impacts TSH levels in patients on levothyroxine, often necessitating dose adjustments. The key implication is that clin…
This landmark study provides strong evidence that current recommendations for discontinuing GLP-1/GIP agonists before upper endoscopy may be overly cautious. The findings suggest that patients can safely continue thei…
This research provides crucial evidence that GLP-1 medicines offer a superior weight loss profile by effectively reducing fat mass while preserving vital muscle mass and function. This finding is particularly signific…